137 related articles for article (PubMed ID: 11936730)
1. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters.
Kalmanti M; Germanakis J; Stiakaki E; Syfridaki C; Christidou A; Tsetis D; Vardas P; Charisis G
Pediatr Hematol Oncol; 2002; 19(3):173-9. PubMed ID: 11936730
[TBL] [Abstract][Full Text] [Related]
2. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
Aquino VM; Sandler ES; Mustafa MM; Steele JW; Buchanan GR
J Pediatr Hematol Oncol; 2002 Dec; 24(9):710-3. PubMed ID: 12468909
[TBL] [Abstract][Full Text] [Related]
3. Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases.
Molinari AC; Haupt R; Saracco P; Di Marco M; Castagnola E; Fratino G
Support Care Cancer; 2004 Dec; 12(12):840-3. PubMed ID: 15365798
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Dillon PW; Jones GR; Bagnall-Reeb HA; Buckley JD; Wiener ES; Haase GM;
J Clin Oncol; 2004 Jul; 22(13):2718-23. PubMed ID: 15226339
[TBL] [Abstract][Full Text] [Related]
5. Intravenous catheter declotting: same outcomes with lower dose urokinase?
Juvé ME
J Infus Nurs; 2003; 26(4):245-51. PubMed ID: 12869858
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients.
Cesaro S; Cavaliere M; Pegoraro A; Gamba P; Zadra N; Tridello G
Ann Hematol; 2016 Apr; 95(5):817-25. PubMed ID: 26961934
[TBL] [Abstract][Full Text] [Related]
7. Incidence of and risk factors for venous thrombosis in children with percutaneous non-tunnelled central venous catheters.
Östlund Å; Fläring U; Norberg Å; Dahlberg A; Berner J; Kaiser S; Vermin L; Svenningsson A; Frisk T; Larsson P; Andersson A
Br J Anaesth; 2019 Sep; 123(3):316-324. PubMed ID: 31176448
[TBL] [Abstract][Full Text] [Related]
8. Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients.
MacLean J; MacDonald T; Digout C; Smith N; Rigby K; Kulkarni K
Pediatr Blood Cancer; 2018 Jun; 65(6):e27015. PubMed ID: 29537717
[TBL] [Abstract][Full Text] [Related]
9. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer.
Arora RS; Roberts R; Eden TO; Pizer B
Cochrane Database Syst Rev; 2010 Dec; (12):CD007785. PubMed ID: 21154387
[TBL] [Abstract][Full Text] [Related]
10. Results of a long-term, prospective study on complications of central venous catheter in pediatric patients with hematologic-oncologic diseases.
Garonzi C; Zeni F; Tridello G; Giacomazzi A; Castagna A; Esposto MP; Caddeo G; Pezzella V; Zaccaron A; Bonetti E; Vitale V; Chinello M; Balter R; Guardini B; Pedrazzoli E; Cesaro S
Pediatr Blood Cancer; 2024 Jul; 71(7):e30990. PubMed ID: 38605511
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer.
Revel-Vilk S; Yacobovich J; Tamary H; Goldstein G; Nemet S; Weintraub M; Paltiel O; Kenet G
Cancer; 2010 Sep; 116(17):4197-205. PubMed ID: 20533566
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
Bagnall HA; Gomperts E; Atkinson JB
Pediatrics; 1989 Jun; 83(6):963-6. PubMed ID: 2657625
[TBL] [Abstract][Full Text] [Related]
13. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
Chesler L; Feusner JH
J Pediatr Hematol Oncol; 2002 Nov; 24(8):653-6. PubMed ID: 12439038
[TBL] [Abstract][Full Text] [Related]
14. Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients.
Jones GR; Konsler GK; Dunaway RP; Lacey SR; Azizkhan RG
J Pediatr Surg; 1993 Mar; 28(3):350-5; discussion 355-7. PubMed ID: 8468645
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients.
De Sio L; Jenkner A; Milano GM; Ilari I; Fidani P; Castellano A; Gareri R; Donfrancesco A
Pediatr Infect Dis J; 2004 Oct; 23(10):963-5. PubMed ID: 15602201
[TBL] [Abstract][Full Text] [Related]
16. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial.
Svoboda P; Barton RP; Barbarash OL; Butylin AA; Jacobs BR; Lata J; Haire WD; Jaff MR; Firszt CM; Mouginis TL; Schuerr DM; Schulz GA; Schwartz LB; El-Shahawy MA
Crit Care Med; 2004 Oct; 32(10):1990-6. PubMed ID: 15483405
[TBL] [Abstract][Full Text] [Related]
17. Clot lysis for thrombosed central venous catheters in pediatric patients.
Kellam B; Fraze D; Kanarek KS
J Perinatol; 1987; 7(3):242-4. PubMed ID: 3504465
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies.
Boersma RS; Jie KS; Verbon A; van Pampus EC; Schouten HC
Ann Oncol; 2008 Mar; 19(3):433-42. PubMed ID: 17962211
[TBL] [Abstract][Full Text] [Related]
19. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices.
Fratino G; Molinari AC; Parodi S; Longo S; Saracco P; Castagnola E; Haupt R
Ann Oncol; 2005 Apr; 16(4):648-54. PubMed ID: 15677621
[TBL] [Abstract][Full Text] [Related]
20. Dilution of urokinase used to treat thrombus formation in central venous catheters.
Wiseman KC
ANNA J; 1997 Aug; 24(4):457-8. PubMed ID: 9325699
[No Abstract] [Full Text] [Related]
[Next] [New Search]
